Slayback Pharmaceuticals
About Slayback Pharmaceuticals
Slayback Pharmaceuticals is a Healthcare company based in West Windsor Township (United States) founded in 2011, and was acquired by Azurity Pharmaceuticals in September 2023. Specialty generic drugs are manufactured with focus on complex injectables. Slayback Pharmaceuticals has raised $110 million across 2 funding rounds from investors including KKR, Everstone Capital and Azurity Pharmaceuticals. Slayback Pharmaceuticals offers products and services including XIFYRM and FIRVANQ. Its focus areas include Traditional Pharmaceuticals, Generics and Injectables. Its legal entity is Azurity Pharmaceuticals, Inc.
Company details
Slayback Pharmaceuticals was founded in 2011 and is based in West Windsor Township, United States. Operations center on the pharmaceutical sector, producing specialty generics through complex formulations including sterile injectables, emulsions, suspensions, microspheres, topical products, foams, aerosols, controlled substances with advanced delivery, and high-bioavailability oral products. FDA approval has been secured for a generic acyclovir ointment targeting herpes infections in specific patient groups.
- Headquarters West Windsor Township, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website slayback-pharma.com
- Social LinkedIn
- Acquired by Azurity Pharmaceuticals (Sep 2023)
- Legal Name Azurity Pharmaceuticals, Inc
- Total Equity Funding$110M (USD)
in 2 rounds
- Latest Funding Round$50M (USD), Series B
Jan 2020
- InvestorsKKR
& 2 more
- Acquired byAzurity Pharmaceuticals
(Sep 2023)
Products & Services of Slayback Pharmaceuticals
Slayback Pharmaceuticals offers a comprehensive portfolio of products and services, including XIFYRM and FIRVANQ.
XIFYRM is utilized for the management of moderate-to-severe pain in adults as an IV non-steroidal anti-inflammatory drug.
FIRVANQ is employed as an anti-infective treatment in various therapeutic contexts.
Funding Insights of Slayback Pharmaceuticals
Slayback Pharmaceuticals has successfully raised a total of $110M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $50 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $110M
- Total Rounds 2
- Last Round Series B — $50M
- First Round $60M
(Dec 2016)
- Investors Count 2
All 2 funding rounds of Slayback Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2020 | $50M | Series B | – | Everstone Capital | |
| Dec 2016 | $60M | Series A | – | KKR | – |
3 investors in total: 3 institutional.
Investors in Slayback Pharmaceuticals
Slayback Pharmaceuticals has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include KKR, Everstone Capital and Azurity Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments in mid-market businesses linked to India and Southeast Asia. | 2006 | everstonecapital.com | Singapore, Singapore | |
Multiple sectors are invested in by this private equity firm. | 1976 | kkr.com | New York, United States | |
Generic drugs are manufactured by Azurity Pharmaceuticals in the US. | 1999 | azurity.com | Woburn, United States |
Investor details for Slayback Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Slayback Pharmaceuticals
30 people are tracked at Slayback Pharmaceuticals (7 in leadership, 3 in board & advisors, 20 in team).
| Name | Role | Group |
|---|---|---|
Ted Smolenski | VP, Business Development | Leadership |
Gyan Ranjan | VP, Operations | Leadership |
Pete Meyers | CFO | Leadership |
Dave Picard | COO | Leadership |
Amol Bhagat | Associate Director | Leadership |
Mallikarjun Patil | Director Of Quality Assurance | Leadership |
Sowmen Porel | Senior Finance Director | Leadership |
Arjun Oberoi | Board Member | Board & advisors |
Puncham Mukim | Board Member | Board & advisors |
Ali J Satvat | Board Member | Board & advisors |
Narayana Reddy | Manager | Team |
Rhina Guritzky | Operations Manager | Team |
Parvateesam Yenda | Manager | Team |
Rajesh Koduri | Manager | Team |
Umangi Soni | Manager | Team |
Royyuru Venkat Ramana | Information Technology Executive | Team |
B Kishore Kumar | Junior Manager | Team |
Durga Prasad Ketha | Senior Manager | Team |
Siny John | Analytical Reviewer | Team |
Balakrishna Reddy Akula | Jr.manager | Team |
10 more people are available in the full profile.
Complete people profiles for Slayback Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Slayback Pharmaceuticals
4 dated milestones of Slayback Pharmaceuticals across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Slayback Pharmaceuticals is founded.
- Funding First funding round of $60.0M.
- Funding Latest funding round, Series B, of $50.0M.
- Exit Acquired by Azurity Pharmaceuticals.
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as Slayback Pharmaceuticals (Traditional Health & Nutrition) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Manufacturer of generics formulations | 2002 | Bridgewater, New Jersey, United States | USD 3.02 B | 8,300 | ||
Biosimilar therapeutics are developed for oncology and autoimmune diseases. | 2010 | Redwood City, California, United States | USD 143.62 M | USD 42.17 M | 228 | |
Ophthalmic pharmaceuticals and instruments are developed for eye care. | 1853 | Bridgewater, New Jersey, United States | USD 5.1 B | 13,500 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Slayback Pharmaceuticals
Slayback Pharmaceuticals was founded in 2011 and raised its 1st funding round 5 years after it was founded.
Slayback Pharmaceuticals is headquartered in West Windsor Township, United States. It is registered at West Windsor Township, New Jersey, United States.
Slayback Pharmaceuticals is a funded company, having raised a total of $110M across 2 funding rounds to date. The company's 1st funding round was a Series A of $60M, raised on Dec 2016.
Slayback Pharmaceuticals was founded in 2011 and is based in West Windsor Township, United States. Operations center on the pharmaceutical sector, producing specialty generics through complex formulations including sterile injectables, emulsions, suspensions, microspheres, topical products, foams, aerosols, controlled substances with advanced delivery, and high-bioavailability oral products. FDA approval has been secured for a generic acyclovir ointment targeting herpes infections in specific patient groups.
Slayback Pharmaceuticals offers XIFYRM and FIRVANQ.
Slayback Pharmaceuticals has 3 investors. Key investors include KKR, Everstone Capital, and Azurity Pharmaceuticals.
Slayback Pharmaceuticals operates through Azurity Pharmaceuticals, Inc.
Yes. Slayback Pharmaceuticals was acquired by Azurity Pharmaceuticals in September 2023.